In this article, the Toxnet group aims to clarify the differences between ‘adjunctive’ and ‘multimodal’ therapy as they are erroneously often used interchangeably which could prevent attainment of treatment goals in spasticity management. Addition of a secondary pharmacologic or non-pharmacologic treatment to optimize the efficacy of the initial modality, is considered an adjunctive therapy. Multimodal therapy is an integrated, patient-centric program of pharmacologic and non pharmacologic strategies utilized in a concurrent/integrated or sequential manner to enhance the overall treatment effect across a variety of spasticity associated impairments. This paper provides a brief evidence-based review of each approach, and insights on selecting multimodal and adjunctive therapies in spasticity management.